Hussman Strategic Advisors Inc. Makes New $1.21 Million Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Hussman Strategic Advisors Inc. acquired a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 63,000 shares of the medical device company's stock, valued at approximately $1,207,000. Hussman Strategic Advisors Inc. owned about 0.09% of Tandem Diabetes Care as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Tandem Diabetes Care by 22.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock worth $236,000 after buying an additional 1,184 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in shares of Tandem Diabetes Care by 17.9% during the first quarter. Oppenheimer Asset Management Inc. now owns 72,752 shares of the medical device company's stock worth $1,394,000 after buying an additional 11,048 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Tandem Diabetes Care by 27.1% during the first quarter. Janney Montgomery Scott LLC now owns 38,450 shares of the medical device company's stock worth $737,000 after buying an additional 8,210 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Tandem Diabetes Care by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock worth $267,989,000 after buying an additional 77,451 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Tandem Diabetes Care by 763.3% during the first quarter. GAMMA Investing LLC now owns 42,190 shares of the medical device company's stock worth $808,000 after buying an additional 37,303 shares in the last quarter.

Tandem Diabetes Care Stock Down 3.8%

Shares of TNDM traded down $0.59 during trading hours on Friday, reaching $14.77. The company's stock had a trading volume of 1,684,780 shares, compared to its average volume of 1,506,260. The firm has a market cap of $983.79 million, a price-to-earnings ratio of -5.31 and a beta of 1.48. Tandem Diabetes Care, Inc. has a 1-year low of $14.66 and a 1-year high of $47.60. The company has a quick ratio of 1.81, a current ratio of 2.30 and a debt-to-equity ratio of 1.99. The company has a 50 day moving average of $19.61 and a two-hundred day moving average of $23.66.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The company had revenue of $234.42 million for the quarter, compared to the consensus estimate of $220.19 million. Tandem Diabetes Care had a negative return on equity of 57.33% and a negative net margin of 18.71%. The firm's revenue for the quarter was up 22.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.65) EPS. As a group, research analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wells Fargo & Company reduced their price target on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 1st. Canaccord Genuity Group lifted their price target on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Stifel Nicolaus reduced their price target on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Mizuho assumed coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 price target on the stock. Finally, Truist Financial began coverage on shares of Tandem Diabetes Care in a research report on Monday, June 16th. They set a "hold" rating and a $24.00 price target on the stock. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $32.71.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.